Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Payables (2019 - 2025)

Bioadaptives' Payables history spans 7 years, with the latest figure at $264821.0 for Q4 2025.

  • Quarterly results put Payables at $264821.0 for Q4 2025, up 25.18% from a year ago — trailing twelve months through Dec 2025 was $264821.0 (up 25.18% YoY), and the annual figure for FY2025 was $264821.0, up 25.18%.
  • Payables for Q4 2025 was $264821.0 at Bioadaptives, down from $590068.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $824132.0 in Q3 2022 to a low of $127298.0 in Q2 2021.
  • The 5-year median for Payables is $497949.0 (2024), against an average of $498772.4.
  • The sharpest move saw Payables surged 355.68% in 2021, then tumbled 72.35% in 2024.
  • Year by year, Payables stood at $281465.0 in 2021, then surged by 181.28% to $791713.0 in 2022, then fell by 3.34% to $765237.0 in 2023, then tumbled by 72.35% to $211554.0 in 2024, then grew by 25.18% to $264821.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $264821.0, $590068.0, and $515081.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.